NEW HAVEN, Conn. - BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company focused on developing medicines in neuroscience through artificial intelligence, has declared a 1-for-16 ...

Hannah joined The Scientist as an assistant editor in 2023. She earned her PhD in neuroscience from the University of Washington in 2017 and completed the Dalla Lana Fellowship in Global Journalism in ...

Scientists at the Salk Institute are unveiling a new brain-mapping neurotechnology ... subtypes will drive the development of ...

DUBLIN--(BUSINESS WIRE)--The "Brain Tumor Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Brain Tumor Therapeutics is ...

To the families who have shared their children's MLD journeys with us: [...]We are committed to advancing our technology into the clinic as quickly as possible.” — Julien Grogg, CEO GENEVA ...

Axial Therapeutics is a clinical-stage biopharmaceutical company harnessing the gut–brain axis (G–BA) to develop safe and effective therapies for patients impacted by central nervous system ...

and OSLO, Norway, Jan. 28, 2025 /PRNewswire/ -- Cordance Medical, a pioneer in non-invasive medical technologies for brain disease treatment, and EXACT Therapeutics (Euronext Growth: EXTX), a ...